Payment overview · 2025
General Payments
$566.71
29 reported records · 11 companies
Healthcare provider profile · identity verified
Amber Elway, DO
Allopathic & Osteopathic Physicians|Family Medicine · MC KEES ROCKS, PA · NPI 1417155847
Verified facts
What the public records show
CMS Open Payments records show Amber Elway, DO received $566.71 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Otezla, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Otezla by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.27 | 26.2% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.74 | 25.2% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $94.91 | 16.8% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.97 | 6.7% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $28.81 | 5.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.49 | 4.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.08 | 3.5% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $19.84 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.79 | 3.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.45 | 3.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.36 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $566.71 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $119.99 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $88.14 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $54.60 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.35 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.97 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $28.81 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OTEZLA otezla |
2025 | Otezla | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 141 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
141 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
191 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 458 | 112 |
| Gabapentin | Gabapentin | 429 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 334 | 54 |
| Lisinopril | Lisinopril | 303 | 70 |
| Oxycodone Hcl | Oxycodone Hcl | 281 | 35 |
| Omeprazole | Omeprazole | 279 | 65 |
| Losartan Potassium | Losartan Potassium | 242 | 65 |
| Potassium Chloride | Potassium Chloride | 212 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 58 |
| Eliquis | Apixaban | 191 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 180 | 43 |
| Sertraline Hcl | Sertraline Hcl | 170 | 37 |
| Metformin Hcl | Metformin Hcl | 159 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 156 | 18 |
| Alendronate Sodium | Alendronate Sodium | 152 | 31 |
| Lorazepam | Lorazepam | 152 | 34 |
| Famotidine | Famotidine | 145 | 41 |
| Furosemide | Furosemide | 144 | 45 |
| Atenolol | Atenolol | 141 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 141 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 26 |
| Prednisone | Prednisone | 130 | 92 |
| Tramadol Hcl | Tramadol Hcl | 126 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 27 |
| Clonazepam | Clonazepam | 117 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 113 | 19 |
| Trazodone Hcl | Trazodone Hcl | 111 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 30 |
| Ibuprofen | Ibuprofen | 108 | 26 |
| Simvastatin | Simvastatin | 107 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 28 |
| Meloxicam | Meloxicam | 100 | 34 |
| Allopurinol | Allopurinol | 99 | 19 |
| Buspirone Hcl | Buspirone Hcl | 96 | 22 |
| Alprazolam | Alprazolam | 93 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 17 |
| Carvedilol | Carvedilol | 86 | 22 |
| Ozempic | Semaglutide | 86 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 25 |
| Donepezil Hcl | Donepezil Hcl | 82 | 13 |
| Jardiance | Empagliflozin | 80 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 15 |
| Cefuroxime | Cefuroxime Axetil | 79 | 64 |
| Azithromycin | Azithromycin | 78 | 68 |
| Bupropion Xl | Bupropion Hcl | 77 | 23 |
| Topiramate | Topiramate | 70 | 11 |
| Mirtazapine | Mirtazapine | 68 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 17 |
| Myrbetriq | Mirabegron | 62 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 19 |
| Levetiracetam | Levetiracetam | 58 | suppressed |
| Diazepam | Diazepam | 54 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 32 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | suppressed |
| Ibu | Ibuprofen | 52 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Cephalexin | Cephalexin | 51 | 24 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 50 | suppressed |
| Rybelsus | Semaglutide | 49 | suppressed |
| Fluconazole | Fluconazole | 48 | 25 |
| Valsartan | Valsartan | 48 | 12 |
| Glipizide | Glipizide | 46 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 13 |
| Meclizine Hcl | Meclizine Hcl | 39 | 20 |
| Bumetanide | Bumetanide | 38 | 13 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 14 |
| Montelukast Sodium | Montelukast Sodium | 36 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 30 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 14 |
| Aprepitant | Aprepitant | 34 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Nystatin | Nystatin | 27 | 16 |
| Ondansetron Odt | Ondansetron | 27 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 21 |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Amantadine | Amantadine Hcl | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Mirabegron Er | Mirabegron | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 13 |
| Risperidone | Risperidone | 18 | suppressed |
| Verapamil Sr | Verapamil Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 11 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Trulance | Plecanatide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Klor-Con 8 | Potassium Chloride | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Miconazole 3 | Miconazole Nitrate | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $566.71 · 29 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, FLOWTRIEVER CATHETER, S, INJECTAFER, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Otezla play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error